Kailera Therapeutics (NASDAQ:KLRA) Sets New 52-Week Low - What's Next?

Key Points

• Kailera Therapeutics shares fell 9.7%, reaching a new 52-week low of $14.76 before closing near $14.84, well below the 50-day moving average of $18.20.
• Analyst views are mixed: some firms issued or maintained sell ratings, while the broader analyst consensus remains “Moderate Buy” with a $42.75 target price.
• The company reported a quarterly loss of $1.09 per share, missing expectations by $0.35, while several institutional investors—including Atlas Venture and Wellington Management—established new positions during the second quarter.

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) reached a new 52-week low during trading on Thursday . The stock traded as low as $14.76 and last traded at $14.84, with a volume of 743672 shares changing hands. The stock had previously closed at $16.43.

Analysts Set New Price Targets

Several research analysts recently commented on KLRA shares. Wall Street Zen lowered shares of Kailera Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 30th. Weiss Ratings began coverage on shares of Kailera Therapeutics in a research note on Friday, August 14th. They issued a "sell (d)" rating for the company. Finally, Zacks Research raised shares of Kailera Therapeutics to a "hold" rating in a report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.75.

Kailera Therapeutics Stock Down 9.7%

The firm has a market capitalization of $1.92 billion and a price-to-earnings ratio of -0.00. The company's fifty day simple moving average is $18.20.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.35). Equities analysts anticipate that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Hedge Funds Weigh In On Kailera Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. acquired a new stake in Kailera Therapeutics during the second quarter worth about $24,233,000. Atlas Venture Life Science Advisors LLC acquired a new stake in shares of Kailera Therapeutics during the 2nd quarter worth approximately $113,923,000. Wellington Management Group LLP purchased a new position in shares of Kailera Therapeutics during the 2nd quarter valued at approximately $64,308,000. Tidal Investments LLC purchased a new stake in Kailera Therapeutics during the second quarter worth $309,000. Finally, Squarepoint Ops LLC acquired a new stake in Kailera Therapeutics during the second quarter valued at $993,000.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.